Inhibitors of cannabinoid receptors and glucose metabolism
Authors:
- André J ScheenASAndré J Scheen
- Nicolas PaquotNPNicolas Paquot
- 1 July 2008
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Clinical Nutrition and Metabolic Care
- Vol. 11 (4) , 505-511
Abstract
Abdominal obesity is closely related to type 2 diabetes and overactivity of the endocannabinoid system. The present review aims at evaluating the role of endocannabinoid system in glucose dysregulation and the effects of cannabinoid 1 receptor blockade on glucose metabolism in both animal models and overweight/obese humans, especially with type 2 diabetes. Cannabinoid 1 receptors have been identified not only in the brain, but also in the adipose tissue, the gut, the liver, the skeletal muscle and even the pancreas, all organs playing a key role in glucose metabolism and type 2 diabetes. Rimonabant, the first selective cannabinoid 1 receptor blocker in clinical use, has been shown to reduce body weight, waist circumference, glycated haemoglobin, triglycerides, insulin resistance index, and to increase HDL cholesterol and adiponectin concentrations in patients with type 2 diabetes, confirming data on nondiabetic overweight/obese patients. Almost half of the metabolic changes, including glycated haemoglobin reduction, could not be explained by weight loss, in agreement with direct peripheral effects. Cannabinoid 1 blockade reduces food intake and body weight and improves metabolic regulation beyond just weight loss. Because of its positive effect on glucose metabolism, rimonabant deserves consideration in the treatment of overweight/obese patients with type 2 diabetes.Keywords
This publication has 54 references indexed in Scilit:
- Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trialsThe Lancet, 2007
- Cannabinoids as therapeutic agents in cardiovascular disease: a tale of passions and illusionsBritish Journal of Pharmacology, 2007
- The endocannabinoid system and rimonabant: a new drug with a novel mechanism of action involving cannabinoid CB1receptor antagonism ? or inverse agonism ? as potential obesity treatment and other therapeutic useJournal of Clinical Pharmacy and Therapeutics, 2007
- Cannabinoid-1 Receptor Antagonist, Rimonabant, for Management of Obesity and Related RisksCirculation, 2006
- Efficacy of Rimonabant and Other Cannabinoid CB1 Receptor Antagonists in Reducing Food Intake and Body Weight: Preclinical and Clinical DataCNS Drug Reviews, 2006
- The Emerging Role of the Endocannabinoid System in Endocrine Regulation and Energy BalanceEndocrine Reviews, 2005
- Endocannabinoid control of food intake and energy balanceNature Neuroscience, 2005
- The endocannabinoid system and its therapeutic exploitationNature Reviews Drug Discovery, 2004
- The endocannabinoid system: a general view and latest additionsBritish Journal of Pharmacology, 2004
- Cannabinoid physiology and pharmacology: 30 years of progressNeuropharmacology, 2004